Serum and CSF levels of soluble interleukin-2 receptors in MS and other neurological diseases: a reappraisal

Chalon, M.P.; Sindic, Christian; Laterre, Emile-Christian

doi:10.1111/j.1600-0404.1993.tb04081.x

Cited by 20 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All sera from the PI subjects were weakly positive for IL-2, and showed increased levels of s I L -~R , while the search for sCD23 gave negative results. In the sera of the N C group, 1L-2 was never detected, sIL-2R were invariably in the range we and others previously found in the normal population (9)(10)(11)(12)(13)(14).…”

Section: Soluble Factorssupporting

confidence: 60%

Effect of high-dose steroid therapy on T-cell subpopulations A longitudinal study in MS patients

Gallo¹,

Chiusole²,

Sanzari

et al. 2009

Acta Neurologica Scandinavica

View full text Add to dashboard Cite

Lymphocyte subpopulations, T cell activation antigens, and serum levels of interleukin 2 (IL‐2) and soluble IL‐2 receptor (sIL2R), were studied in relapsing‐remitting MS (RR‐MS) patients before and after high‐dose steroid therapy. Prior to therapy, a minority of patients showed increased HLA‐DR antigen expression, and an increased number of CD16 + and CD19+ cells. Steroid treatment induced a significant increase in HLA‐DR and CD 19 expression, a significant reduction in CD 16 +, CD57 +, and CD8 + CD57 + cells, and a slight, non‐significant, decrease in IL‐2 and sIL‐2R levels and CD25 expression on CD4 + T lymphocytes.

show abstract

Section: Soluble Factorssupporting

confidence: 60%

Effect of high-dose steroid therapy on T-cell subpopulations A longitudinal study in MS patients

Gallo¹,

Chiusole²,

Sanzari

et al. 2009

Acta Neurologica Scandinavica

View full text Add to dashboard Cite

show abstract

“…While no previous studies have examined CSF sIL-2R levels in NMOSD patients, several have examined them in MS patients, but they reported conflicting results, including elevated 6,7 or normal levels. 8,9 Similarly, several studies have examined CSF IL-10 levels in patients with MS or NMOSD, but they also had conflicting results, including elevated 10 or normal levels. 11–13 We therefore reassessed CSF sIL-2R and IL-10 levels in CNS IDD and CNS tumor patients using an alternative method.…”

Section: Discussionmentioning

confidence: 99%

“…4,5 Previous studies examining CSF sIL-2R levels in MS have reported conflicting results, including elevated 6,7 or normal levels. 8,9 Studies examining CSF IL-10 levels in MS or NMOSD have also reported both elevated 10 and normal levels. 11–13 Moreover, few previous studies directly compared CSF measures in CNS IDDs and CNS tumors.…”

Section: Introductionmentioning

confidence: 99%

CSF and clinical data are useful in differentiating CNS inflammatory demyelinating disease from CNS lymphoma

Ikeguchi

Shimizu

et al. 2017

Mult Scler

View full text Add to dashboard Cite

show abstract

“…72 However, elevations of sIL2R in the CSF may also be seen in patients with intracerebral infections or malignancies. 72,73 Peripheral Nervous System Testing Electromyoneurography (EMNG) is useful for confirmation of suspected peripheral nerve or muscle sarcoidosis (►Fig. 8).…”

Section: Cerebrospinal Fluidmentioning

confidence: 99%

Neurosarcoidosis

Neto

Moss

Willis

et al. 2017

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Neurosarcoidosis is an uncommon but clinically significant manifestation that will be routinely encountered in sarcoidosis specialty clinics. Overall, neurologic involvement is recognized in 5 to 10% of individuals with sarcoidosis. Neurologic symptoms will be the presenting manifestation of sarcoidosis in approximately one-half of those with neurosarcoidosis. The clinical and imaging features of neurosarcoidosis vary widely, largely depending on the anatomic distribution of the disease. The likelihood of spontaneous resolution is lower than for sarcoidosis in general, and residual functional deficits are not uncommon. Therefore, most patients with neurosarcoidosis require immunosuppressive therapy. Small fiber neuropathy, a recently recognized nongranulomatous parasarcoidosis syndrome, is prevalent in chronic sarcoidosis. The variety of neurologic manifestations, broad differential diagnosis, and complexity of management render neurosarcoidosis an area best served by multidisciplinary teams. Sarcoidologists, neurologists, radiologists, neurosurgeons, endocrinologists, urologists, physiatrists, and physical/occupational therapists all potentially have important roles.

show abstract

Serum and CSF levels of soluble interleukin-2 receptors in MS and other neurological diseases: a reappraisal

Cited by 20 publications

References 19 publications

Effect of high-dose steroid therapy on T-cell subpopulations A longitudinal study in MS patients

Effect of high-dose steroid therapy on T-cell subpopulations A longitudinal study in MS patients

CSF and clinical data are useful in differentiating CNS inflammatory demyelinating disease from CNS lymphoma

Neurosarcoidosis

Contact Info

Product

Resources

About